











| Numéro de catalogue | HW431026 |
|---|---|
| Description |
Iladatuzumab (HW431026) is a research-grade recombinant antibody targeting CD79B. Produced in mammalian cells with native-like glycosylation.
Highlights
|
| Reactivité des espèces | Human |
| Applications | ELISA, Bioactivity: FACS, Functional assay, Research in vivo |
| Espèce hôte | Human |
| Clonalité | Monoclonal |
| Isotype | IgG1-kappa |
| Système d'expression | Mammalian cells |
| Applications testées | WB, FCM |
| Cible | B-cell-specific glycoprotein B29, CD79B, B-cell antigen receptor complex-associated protein beta chain, Ig-beta, B29, Immunoglobulin-associated B29 protein, IGB, CD79b |
| Niveau d'endotoxines | < 10 EU/mg |
| Pureté | >95% purity as determined by SDS-PAGE. |
| Purification | Protein A/G purified from cell culture supernatant. |
| Numéro d'accès | P40259 |
| Forme | Liquid |
| Tampon de stockage | 0.01M PBS pH 7.4 Reférez-vous aux informations spécifiques sur le tampon dans la copie papier du datasheet ou dans le COA spécifique au lot. |
| Stabilité et stockage | Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8°C for frequent use. Store at -20 to -80°C for twelve months from the date of receipt. |
| Noms alternatifs | DCDS0780A, MCDS0593A, RO7032005, 1906205-76-2 |
| Contexte | B-cell antigen receptor complex-associated protein beta chain (CD79B) is a ~26 kDa protein. Required in cooperation with CD79A for initiation of the signal transduction cascade activated by the B-cell antigen receptor complex (BCR) which leads to internalization of the complex, trafficking to late endosomes and antigen presentation. Enhances phosphorylation of CD79A, possibly by recruiting kinases which phosphorylate CD79A or by recruiting proteins which bind to CD79A and protect it from dephosphorylation. CD79B is the therapeutic target of polatuzumab vedotin (Polivy). |
| Note | For research use only. Not suitable for clinical or therapeutic use. |
| Isotype Control | Anti-LASV GPC Recombinant Antibody (Fab 37.7) (VK453013) |

Detects CD79β/CD79B in indirect ELISAs.

SDS-PAGE for Research Grade Iladatuzumab

Western blot analysis was performed using anti-CD79β/CD79B monoclonal antibody at 1μg/ml on various samples.
Lane 1: recombinant human CD79β/CD79B (Catalog No: HW431011)

Flow-cytometry using APC anti-human CD79B antibody. Daudi cells were stained with an irrelevant antibody (Blue Histogram) or an APC anti-human CD79B monoclonal antibody (Catalog HW431026, Yellow Histogram) at a concentration of 5 µg/ml for 30 mins at RT. After washing, and cells analysed on a NovoCyte Flow Cytometer.

Flow-cytometry using PE anti-human CD79B antibody. Daudi cells were stained with an irrelevant antibody (Blue Histogram) or an PE anti-human CD79B monoclonal antibody (Catalog HW431026, Yellow Histogram) at a concentration of 5 µg/ml for 30 mins at RT. After washing, and cells analysed on a NovoCyte Flow Cytometer.

Flow-cytometry using FITC anti-human CD79B antibody. Daudi cells were stained with an irrelevant antibody (Blue Histogram) or an FITC anti-human CD79B monoclonal antibody (Catalog HW431026, Yellow Histogram) at a concentration of 5 µg/ml for 30 mins at RT. After washing, and cells analysed on a NovoCyte Flow Cytometer.




Contactez-nous pour les devis personnalisés, les demandes en gros et tout autre problème.
Courrier : [email protected]












+86-027-65523339
Bâtiment C, No. 666, Rue Shendunsi, Wuhan, 430206, Chine
中文
English
한국어
日本語
Español
Français
Русский